1. Cellular heterogeneity of pluripotent stem cell-derived cardiomyocyte grafts is mechanistically linked to treatable arrhythmias.
- Author
-
Selvakumar D, Clayton ZE, Prowse A, Dingwall S, Kim SK, Reyes L, George J, Shah H, Chen S, Leung HHL, Hume RD, Tjahjadi L, Igoor S, Skelton RJP, Hing A, Paterson H, Foster SL, Pearson L, Wilkie E, Marcus AD, Jeyaprakash P, Wu Z, Chiu HS, Ongtengco CFJ, Mulay O, McArthur JR, Barry T, Lu J, Tran V, Bennett R, Kotake Y, Campbell T, Turnbull S, Gupta A, Nguyen Q, Ni G, Grieve SM, Palpant NJ, Pathan F, Kizana E, Kumar S, Gray PP, and Chong JJH
- Subjects
- Animals, Humans, Disease Models, Animal, Myocardial Infarction therapy, Swine, Cells, Cultured, Cell Differentiation, Induced Pluripotent Stem Cells transplantation, Action Potentials physiology, Action Potentials drug effects, Phenotype, Biomarkers metabolism, Pluripotent Stem Cells transplantation, Stem Cell Transplantation methods, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents pharmacology, Heart Rate physiology, Myocytes, Cardiac metabolism, Myocytes, Cardiac transplantation, Arrhythmias, Cardiac therapy
- Abstract
Preclinical data have confirmed that human pluripotent stem cell-derived cardiomyocytes (PSC-CMs) can remuscularize the injured or diseased heart, with several clinical trials now in planning or recruitment stages. However, because ventricular arrhythmias represent a complication following engraftment of intramyocardially injected PSC-CMs, it is necessary to provide treatment strategies to control or prevent engraftment arrhythmias (EAs). Here, we show in a porcine model of myocardial infarction and PSC-CM transplantation that EAs are mechanistically linked to cellular heterogeneity in the input PSC-CM and resultant graft. Specifically, we identify atrial and pacemaker-like cardiomyocytes as culprit arrhythmogenic subpopulations. Two unique surface marker signatures, signal regulatory protein α (SIRPA)
+ CD90- CD200+ and SIRPA+ CD90- CD200- , identify arrhythmogenic and non-arrhythmogenic cardiomyocytes, respectively. Our data suggest that modifications to current PSC-CM-production and/or PSC-CM-selection protocols could potentially prevent EAs. We further show that pharmacologic and interventional anti-arrhythmic strategies can control and potentially abolish these arrhythmias., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF